Head and neck cancer
Head and neck cancer is the seventh most common type of cancer worldwide and comprise
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and …
Background Chemoradiotherapy is the standard of care for unresected locally advanced
squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab …
squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab …
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC)
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck …
Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …
with programmed cell death ligand 1 (PD-L1) expression associated with improved …
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing
Head and neck squamous cell carcinoma (HNSCC) is characterized by complex relations
between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To …
between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To …
The changing therapeutic landscape of head and neck cancer
Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised …
Background There are few effective treatment options for patients with recurrent or
metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour …
metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour …
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …